Humacyte, Inc. (HUMA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US44486Q1031
Humacyte, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 2.04 m USD |
| Gross profit | -7.66 m USD |
| Operating income | -108.14 m USD |
| EBIT | -32.17 m USD |
| Net income | -40.83 m USD |
| Diluted EPS – continuing operations | -0.26 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Humacyte, Inc.
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
More stocks
- Bakkt, Inc. (BKKT)
- Vireo Growth Inc. (VREOF)
- Crexendo, Inc. (CXDO)
- Seoul City Gas (017390.KS)
- QBeyond (QBY.DE)
- Dafeng TV Ltd (6184.TW)
- Sriracha Construction Public Company Limited (SRICHA.BK)
- Zentalis Pharmaceuticals, Inc. (ZNTL)
- VANJIA CORP (VNJA)
- Benfica (SLBEN.LS)
- Gs Global (001250.KS)
- Nitrasanata Dharma Tbk (JECX.JK)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.